Wire · opportunities
Stocktwits Biotech Dealmaker — Novartis, Sanofi And Novo Sign Week's Biggest Deals
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 3 October 2026 · Fusion42 review
Novartis, Sanofi, and Novo Nordisk signed major biotech deals this week focusing on RNA immune drugs, long-acting inflammation antibodies, and obesity treatments, with significant upfront payments and milestone-based valuations. AstraZeneca and Merck also invested heavily in early-stage cancer drugs.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
Biotech founders working on RNA immune therapies and metabolic disease treatments should watch China closely as big players like Novartis and Novo Nordisk buy early rights with billions in payments. Your best inroads may come from partnering on next-gen autoimmune and obesity drugs where incumbents are locking in assets aggressively.
◆ Coverage
1 source · 3 Oct 2026
◆ Related on Wire
◆ Topics